{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:11Z","timestamp":1790612111676,"version":"4.1.0"},"reference-count":46,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2010,8,18]],"date-time":"2010-08-18T00:00:00Z","timestamp":1282089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:sec><jats:label\/><jats:p><jats:italic>Aliment Pharmacol Ther<\/jats:italic>2010;<jats:bold>32:<\/jats:bold>1000\u20131006<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold>Abnormal intestinal clearance is involved in the pathogenesis of small intestinal bacterial overgrowth (SIBO). It is known that partially hydrolysed guar gum affects intestinal motility. Eradication therapy of SIBO is based on antibiotic treatment: no data are available on the role of fibre supplementation in eradicating SIBO.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold>To assess whether the combination of partially hydrolysed guar gum and rifaximin is more effective than rifaximin alone in the treatment of SIBO.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold>A 50\u2003g\u2010glucose breath test was given to 500 consecutive patients. Patients with a positive glucose breath test and predisposing conditions to SIBO entered into the study, and were randomized to receive rifaximin 1200\u2003mg\/day or rifaximin 1200\u2003mg\/day plus partially hydrolysed guar gum 5\u2003g\/day for 10\u2003days. Patients completed a symptom questionnaire and glucose breath test both in basal condition and 1\u2003month after withdrawal of therapy.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold>Seventy\u2010seven patients had SIBO. Eradication rate of SIBO was 62.1% in the rifaximin group (both on per\u2010protocol and intention\u2010to\u2010treat analyses), and 87.1% (per\u2010protocol,<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.017) and 85.0% (intention\u2010to\u2010treat,<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.036) in the rifaximin\u2010plus\u2010partially hydrolysed guar gum group. Clinical improvement was observed in 86.9% and 91.1% of eradicated cases in rifaximin and rifaximin\u2010plus\u2010partially hydrolysed guar gum groups respectively (<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.677).<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold>The combination of rifaximin with partially hydrolysed guar gum seems to be more useful in eradicating SIBO compared with rifaximin alone.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2010.04436.x","type":"journal-article","created":{"date-parts":[[2010,8,19]],"date-time":"2010-08-19T04:57:56Z","timestamp":1282193876000},"page":"1000-1006","source":"Crossref","is-referenced-by-count":73,"title":["Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth"],"prefix":"10.1111","volume":"32","author":[{"given":"M.","family":"Furnari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Parodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gemignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. G.","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Marenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Assandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Inferrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,18]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000081988"},{"key":"e_1_2_6_3_2","first-page":"200","article-title":"Enteric bacterial flora and bacterial overgrowth syndrome","volume":"13","author":"Gregg CR","year":"2002","journal-title":"Semin Gastrointest Dis"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000171170"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01016.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.52.7.503"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0016-5085(82)80403-4","article-title":"Hepatic steatosis after intestinal bypass\u2010prevention and reversal metronidazole, irrespective of protein\u2010calorie malnutrition","volume":"82","author":"Drenick EJ","year":"1982","journal-title":"Gastroenterology"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2008.02.054"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.7.852"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3181a099a5"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-8-200610170-00004"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.108712"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.06.031"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2008.01142.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(90)90818-L"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.2628"},{"issue":"1","key":"e_1_2_6_17_2","first-page":"18","article-title":"H2\u2010breath testing for small\u2010intestinal bacterial overgrowth","volume":"29","author":"Parodi A","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3180536784"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02516.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03259.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543780902780175"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01758.x"},{"key":"e_1_2_6_23_2","first-page":"1617","volume-title":"Textbook of Gastroenterology","author":"Ellen L","year":"2003"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2509"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-0606"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-002-0396-5"},{"key":"e_1_2_6_27_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2036.1995.tb00348.x","article-title":"Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double\u2010blind placebo controlled trial","volume":"3","author":"Papi C","year":"1995","journal-title":"Aliment Pharcol Ther"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-005-2478-z"},{"key":"e_1_2_6_29_2","first-page":"111","article-title":"Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole","volume":"13","author":"Lauritano EC","year":"2009","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6622.615"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/284283a0"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0269-2813.2004.01862.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91055-3"},{"key":"e_1_2_6_34_2","volume-title":"Sub\u2010Chronic (13\u2003Week) Oral Toxicity Study With Sunfiber and Sunfiber ST in Rats","author":"Lina BAR","year":"1997"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0271-5317(05)80557-3"},{"key":"e_1_2_6_36_2","first-page":"21","article-title":"Gomma guar parzialmente idrolizzata: una fibra come coadiuvante nella sindrome del colon irritabile","volume":"152","author":"Giaccari S","year":"2001","journal-title":"Clin Ter"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2005.10.003"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.3177\/jnsv.40.251"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1079\/BJN2001394"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/125.6.1401"},{"key":"e_1_2_6_41_2","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/jn\/126.8.1979","article-title":"Dietary guar gum alters colonic microbial fermentation in azoxymethane\u2010treated rats","volume":"126","author":"Weaver GA","year":"1996","journal-title":"J Nutr"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1271\/bbb.58.1364"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2007.08.002"},{"key":"e_1_2_6_44_2","first-page":"19","volume-title":"Chronic Constipation","author":"Philips SF","year":"1996"},{"key":"e_1_2_6_45_2","first-page":"1795","article-title":"The lactulose breath hydrogen test and small intestinal bacterial overgrowth","volume":"91","author":"Riordan SM","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1590-8658(10)60158-2"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.12.022"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2010.04436.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2010.04436.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T20:01:02Z","timestamp":1740427262000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2010.04436.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,18]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1365-2036.2010.04436.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04436.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,18]]}}}